Bank of America analysts on Friday told investors that Eli Lilly & Co. Inc.’s LLY diabetes treatment and possible weight-management drug could be a $100 billion medication. The drug, tirzepatide, received Food and Drug Administration approval as a treatment for Type 2 diabetes earlier this year. It has also shown in clinical trials that it can help people lose up to 20% of their body weight. Lilly said this week that the experimental obesity drug now has a Fast Track designation from the FDA, and the company plans to begin a rolling submission as it seeks approval for a weight-loss indication. “Expansion into other indications such as NASH, sleep apnea, kidney disease, and heart failure could eventually make tirzepatide the first $100B product in the biopharma industry,” the analysts wrote. Lilly’s stock has gained 19.0% so far this year, while the broader S&P 500 SPX is down 21.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0